Anti-inflammatory pharmacotherapy during pregnancy

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 571-580

  Østensen, Monika E ^a   Skomsvoll, Johan F ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Aspirin; Congenital malformation; Cyclooxygenase; Fetal effects; Fetal growth restriction; Glucocorticosteroids; Infertility; Inhibitors; Miscarriage

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETAMETHASONE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; DEXAMETHASONE; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; INTERLEUKIN 12; ISOENZYME; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PIROXICAM; PREDNISONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLIC ACID; SULINDAC; THROMBOXANE; UNINDEXED DRUG;

ACIDOSIS; ADRENAL CORTEX INSUFFICIENCY; ANURIA; ARTERY CONSTRICTION; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLEFT LIP PALATE; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS OBLITERATION; ENZYME INHIBITION; FEMALE; FEMALE INFERTILITY; FEVER; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; GASTROSCHISIS; GESTATIONAL AGE; HUMAN; INFERTILITY; INTRAUTERINE GROWTH RETARDATION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY MALFORMATION; LOW BIRTH WEIGHT; LYMPHOCYTOPENIA; NONHUMAN; OLIGOHYDRAMNIOS; OVULATION INHIBITION; PAIN; PERINATAL INFECTION; PLACENTAL TRANSFER; PREGNANCY; PREMATURE LABOR; PREMATURITY; PULMONARY HYPERTENSION; REPRODUCTION; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY;

EID: 1542505424     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.571     Document Type: Review

References (95)

1. DANNHARDT G, KIEFER W: Cyclooxygenase inhibitors - current status and future prospects. Eur J. Med. Chem. (2001) 36:109-126.
2. DUBOIS RN, ABRAMSON SB, CROFFORD L et al.: Cyclooxygenase, in biology and disease. FASEB J. (1998) 12:1063-1073.
3. LIPSKY PE, BROOKS P, CROFFORD L et al.: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. (2000) 160:913-920.
4. COOMARASAMY A, HONEST H, PAPAIOANNOU S, GEE H, KHAN KS: Aspirin for prevention of preeclampsia in women with historical risk factors: A systematic review. Obstet. Gynecol. (2003) 101:1319-1332.
5. BRANCH DW, KHAMASHTA OA: Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet. Gynecol. (2003) 101:1333-1344.
6. YUSSOFF DAWOOD M: Nonsteroidal antiinflammatory drugs and reproduction. Am. J. Obstet. Gynecol. (1993) 169:1255-1265.
7. ØSTENSEN M: Prescribing in pregnancy - Rheumatological disorders. Best Pract Res Clin. Obstet. Gynecol. (2001) 15:953-969.
8. ØSTENSEN M, FUHRER L, MATHIEU R, SEITZ M, VILLIGER PM: A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann. Rheum. Dis. (In Press).
9. PETRI M: Pregnancy in SLE. Baillière's Clin. Rheumatol. (1998) 12:449-476.
10. OLIW EH: Oxygenation of polyunsaturated fatty acids by cytochrome P-monooxygenases. Prog. Lipid Res. (1994) 33:329-354.
11. YOSHIDA S, AMANO H, HAYASHI I et al.: COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab. Invest. (2003) 83:1385-1394.
12. CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc. Natl. Acad. Sci. USA (2002) 99:13926-13931.
13. BOTTING R: COX-1 and COX-3 inhibitors. Thromb. Res. (2003) 110:269-272.
14. SIMMONS DL: Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. (2003) 110:265-268.
15. TEGEDER I, PFEILSCHIFTER J, GEISSLINGER G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. (2001) 15:2057-2072.
16. MENDONCA LLF, KHAMASHTA MA, NELSON-PIERCY C, HUGHES GRV: Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatolgy (2000) 39:880-882.
17. UHLER ML HSU JW, FISHER SG, ZINAMAN MJ: The effect of nonsteroidal antiinflammatory drugs on ovulation: A prospective, randomized clinical trial. Fertil. Steril. (2001) 76:957-961.
18. PALL M, FRIDEN BE, BRANNSTROM M: Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: A randomized double blind study. Hum. Reprod. (2001) 16:1323-1328.
19. REESE J, ZHAO X, MA WG, BROWN N, MAZIASZ TJ, DEY SK: Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology (2001) 142:3198-3206.
20. SOOKVANICHSILP N, PULBUTR P: Anti-implantation effects of indomethacin and celecoxib in rats. Contraception (2002) 65:373-378.
21. CHENG JG, STEWART CL: Loss of cyclooxygenase-2 retards decidual growth but does not inhibit embryo implantation or development to term. Biol. Reprod. (2003) 68:401-404.
22. JACOBSON RL, BREWER A, EIS A, SIDDIQI TA, MYATT L: Transfer of aspirin across the perfused human placental cotyledon. Am. J. Obstet. Gynecol. (1991) 165:939-44.
23. LAMPELA ES, NUUTINEN LH, ALA-KOKKO TI et al.: Placental transfer of sulindac, sulindac sulfide, and indomethacin in a human placental perfusion model. Am. J. Obstet. Gynecol. (1999) 180(1 Pt 1):174-180.
24. SIU SS, YEUNG JH, LAU TK: An in-vivo study on placental transfer of naproxen in early human pregnancy. Hum. Reprod. (2002) 17(4):1056-1059.
25. SIU SS, YEUNG JH, LAU TK: A study on placental transfer of diclofenac in first trimester of human pregnancy. Hum. Reprod. (2000) 15(11):2423-2425.
26. ØSTENSEN M: Safety of non-steroidal anti-inflammatory drugs during pregnancy and lactation. Inflammopharmacology (1996) 4:31-41.
27. MACONES GA, MARDER SJ, CLOTHIER B, STAMILIO DM: The controversy surrounding indomethacin for tocolysis. Am. J. Obstet. Gynecol. (2001) 184:264-272.
28. Drugs in pregnancy and Lactation (6th edn). Briggs GG, Freeman RK, Yaffe SJ (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002).
29. NIELSEN GL, SORENSEN HT, LARSEN H, PEDERSEN L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: Population based observational study and case-control study. Br. Med. J. (2001) 322:266-270.
30. CHAN LY, YUEN PM: Risk of miscarriage in pregnant users of NSAIDs. More information is needed to be able to interpret study's results. Br. Med. J. (2001) 322:1365-1366.
31. LI DK, LIU L, ODOULI R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br. Med. J. (2003) 327:368-373.
32. Birth defects and drugs in pregnancy. Heinonen OP, Slone D, Shapiro S (Eds), Littleton Publishing Sciences Group, Littleton, MA, USA (1977):286-295.
33. KÄLLÈN B: The teratogenicity of antirheumatic drugs - what is the evidence? Scand. J. Rheumatol. (1998) 27(Suppl. 107):119-124.
34. SKOMSVOLL JF, ØSTENSEN M, IRGENS LM, BASTE V: Perinatal outcome in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand. J. Rheumatol. (1999) 28:352-356.
35. WISE LD, CUKIERSKI MA, SHELLY LA, PATRICK DH: Effect of a COX-2 inhibitor, rofecoxib, on closure of the fetal rat ductus arteriosus.
36. BURDAN F: Prenatal effects of DuP-697- the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod. Toxicol. (2000) 317:413-419.
37. COOK JC, JACOBSON CF, GAO F, TASSINARI MS, HURTT ME, DESESSO JM: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68:5-26.
38. TASSINARI M, COOK JC, HURT ME: NSAIDs and developmental toxicity. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68:3-4.
39. CAPPON GD, COOK JC, HURTT ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68(1):47-56.
40. SADOVSKY Y, NELSON DM, MUGLIA LJ et al.: Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase Type 2. Am. J. Obstet. Gynecol. (2000) 182(2):370-376.
41. LEWIS RB, SCHULMAN JD: Influence of acetylicsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour Lancet (1973) 2:1159-1161.
42. SAWDY RJ, LYE S, FISK NM, BENNETT PR: A double-blind randomised study of fetal side effects during and after short-term maternal administration of indomethacin, sulindac, and nimesulide for therapy of preterm labor. Am. J. Obstet. Gynecol. (2003) 188:1046-1051.
43. LOCATELLI A, VERGANI P, BELLINI P, STROBELT N, GHIDINI A: Can a cyclooxygenase type- 2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG (2001) 108:325-326.
44. STIKA CS, GROSS GA, LEGUIZAMON G et al.: A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am. J. Obstet. Gynecol. (2002) 187:653-660.
45. STANFIELD KM, BELL RR, LISOWSKI AR, ENGLISH ML, SALDEEN SS, KHAN KN: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res. Part A Clin. Mol. Teratol. (2003) 67:54-58.
46. MOMMA K, TAKEUCHI H: Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins (1983) 26:631-643.
47. LOFTIN CD, NORTON ME, MERRIL J, COOPER BAB, KULLER JA, CLYMAN RI: Neonatal complications after the administration of indomethacin for preterm labor. N. Engl. J. Med. (1993) 329:1602-1607.
48. VERMILLION ST, SCARDO JA, LASHUS AG et al.: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am. J. Obstet. Gynecol. (1997) 177:256-261.
49. VAN DEN VEYVER IB, MOISE KJ JR, OU CN, CARPENTER RJ JR. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet. Gynecol. (1993) 82:500-503.
50. TULZER G, GUDMUNDSSON S, SHARKEY AM, WOOD DC, COHEN AW, HUHTA JC: Doppler echocardiography of fetal ductus arteriosus constriction versus increased right ventricular output. J. Am. Coll. Cardiol. (1991) 18:532-536.
51. NORTON ME: Fetal effects of Indomethacin administration during pregnancy. Teratology (1997) 56:282-292.
52. ALANO MA, NGOUGMNA E, OSTREA EM JR, KONDURI GG: Analysis of nonsteroidal antiinflammatory drug in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics (2001) 107:519-523.
53. HICKOK DE, HOLLENBACH KA, REILLEY SF et al.: The association between decreased amniotic fluid volume and treatment with nonsteroidal antiinflammatory agents for preterm labor. Am. J. Obstet. Gynecol. (1989) 160:1525-1531.
54. VAN DER HEIJDEN B, GUBLER MC: Renal failure in the neonate associated with in utero exposure to non-steroidal antiinflammatory agents. Pediatr. Nephrol. (1995) 9:675.
55. LLANAS B, CAVERT MH, APERE H et al.: Les effets secondaires du ketoprofène après exposition intra-utérine. Intérêt du dosage plasmatique. Arch. Pediatr. (1996) 3:248-253.
56. KAJINO H, ROMAN C, CLYMAN RI: Renal effects of cyclooxygenase-2 inhibition in fetal lambs. Biol. Neonate (2002) 82:257-262.
57. MERTZ HL, LIU J, VALEGO NK, STALLINGS SP, FIGUEROA JP, ROSE JC: Inhibition of cyclooxyEenase-2: effects on renin secretion and expression in fetal lambs. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284:1010-1011.
58. PERUZZI L, GIANOOGLIO B, PORCELLINI G, CONTI G, AMORO A, COPPO R: [Neonatal chronic kidney failure associated with cyclooxygenase-2 inhibitors administered during pregnancy]. Minerva Urol. Nefrol. (2001) 53:113-116.
59. KOZER E, MOLDOVAN COSTEI A, BOSKOVIC R, NULMAN I, NIKFAR S, KOREN G: Effects of aspirin consumption during pregnancy on pregnancy outcomes: Meta-analysis. Birth Defects Res. Part B Dev. Reprod. Toxicol. (2003) 68:70-84.
60. VAINIO M, KUJANSUU E, ISO-MUSTAJARVI M, MAENPAA J: Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG (2002) 109:161-167.
61. OZTURK O, GREAVES M, TEMPLETON A: Aspirin dilemma. Remodelling the hypothesis from a fertility perspective. Hum. Reprod. (2002) 17:1146-1148.
62. HERTZ-PICCIOTTO I, HOPENHAYN-RICH C, GOLUB M, HOOPER K: The risks and benefits of taking aspirin during pregnancy. Epidemiol. Rev. (1990) 12:108-148.
63. SLONE D, HEINONEN OP, KAUFMAN DW, SISKIND V, MONSON RR, SHAPIRO S: Aspirin and congenital malformations. Lancet (1976) 2:1373-1375.
64. KARON A, HONEIN MA, MOORE CA. Maternal febbrile illnesses, medication use, and the risk of congenital renal anomalies. Birth Defects Res. Part A Clin. Mol. Teratol. (2003) 67:911-918.
65. KOZER E, SHEKOUFEH N, COSTEI A, BOSKOVIC R, NULMAN I, KOREN G: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. Am. J. Obstet. Gynecol. (2002) 187:1623-1630.
66. WERLER MM, SHEEHAN JE, MITCHELL AA: Maternal medication use and risks of gastroschisis and small intestinal atresia. Am. J. Epidemiol. (2002) 155:26-31.
67. MARTINEZ-FRIAS ML, RODRIGUEZ-PINILIA E, PRIETO L: Prenatal exposure to salicylates and gastroschisis: A case-control study. Teratology (1997) 56(4):241-243.
68. WERLER MM, MITCHELL AA, SHAPIRO S: First trimester maternal medication use in relation to gastroschisis. Teratology (1992) 45(4):361-367.
69. STUART MJ, GROSS SJ, ELRAD H, GRAEBER JE: Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N. Engl. J. Med. (1982) 307:909-912.
70. RUMACK CM, GUGGENHEIM MA, RUMACK BH et al.: Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet. Gynecol. (1981) 58(Suppl.):52S-56S.
71. LEONHARDT A, BERNERT S, WATZER B, SCHMITZ-ZIEGLER G, SEYBERTH HW: Low-dose aspirin in pMegnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics (2003) 111:e77-e81.
72. DI SESSA TG, MORETTI ML, KHOURY A et al.: Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am. J. Obstet. Gynecol. (1994) 171:892-900.
73. PINSKY L, DIGEORGE AMA Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science (1965) 147:402-403.
74. FRASER FC, SAJOO A: Teratogenic potential of corticosteroids in humans. Teratology (1995) 51:45-46.
75. RODRIGUEZ-PINILLA E, MARTINEZ-FRIAS ML: Corticosteroids during pregnancy and oral clefts: A case-control study. Teratology (1998) 58:2-5.
76. CARMICHAEL SL, SHAW GM: Maternal corticosteroid use and risk of selected congenital anomalies. Teratology (1999) 86:242-244.
77. PARK-WYLLIE L, MAZZOTTA P, PASTUSZAK A et al.: Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology (2000) 62:385-392.
78. EDWARDS MJ, AGHO K, ATTIA J et al.: Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am. J. Med. Genet. (2003) 120:459-463.
79. MYGIND H, THULSTRUP AM, PEDERSEN L, LARSEN H: Risk of intrauterine growth retardation, malformations, and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet. Gynecol. Scand. (2002) 81:234-239.
80. CZEIZEL AE, ROCKENBAUER M: Population-based case-control study of teratogenic potential of corticosteroids. Teratology (1997) 56:335-340.
81. PRADAT P, ROBERT-GNANSIA E, DI TANNA GL et al.: First trimester exposure to corticosteroids and oral clefts. Birth Defects Res. Part A Clin. Mol. Teratol. (2003) 67:968-970.
82. REINISCH JM, SIMON NG: Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science (1978) 202:436-438.
83. SCOTT JR: Fetal growth retardation associated with maternal administration of immunosuppressives. Am. J. Obstet. Gynecol. (1977) 128:668-676.
84. CZEIZEL AE: Birth weight, gestational age and medications during pregnancy. Int. J. Gynaecol. Obstet. (1998) 60:245-249.
85. COWCHOCK FS, REECE EA, BALABAN D, BRANCH DW, PLOUFFE L: Repeated fetal losses associated with antiphospholipid antibodies, a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. (1992) 166-1318-1323.
86. CEDERQVIST LL, MERKATZ IR, LITWIN SD: Fetal immunoglobin synthesis following maternal immunosuppression. Am. J. Obstet. Gynecol. (1977) 129:687-690.
87. COTÉ CJ, MEUWISSEN HG, PICKERING RJ: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J. Pediatr. (1974) 85:324-328.
88. SCHMIDT PL, SIMS ME, STRASSNER HT et al.: Effect of antepartum glucorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. Am. J. Obstet. Gynecol. (1994) 178:178-1786.
89. CLARK DA, BANWATT D, CHAOUAT G: Effect of prostaglandin synthesis inhibitors on spontaneous and endotoxin-induced abortion in mice. J. Reprod. Immunol. (1993) 24(1):29-44.
90. TINCANI A, BRANCH W, LEVY RA et al.: Treatment of pregnant patients with antiphospholipid sydrome. Lupus (2003) 12:524-529.
91. PAR G, BARTOK B, SZEKERES-BARTHO J: Cyclooxygenase is involved in the effects of progesterone-induced blocking factor on the production of interleukin 12. Am. J. Obstet. Gynecol. (2000) 183:126-130.
92. ØSTENSEN M, ØSTENSEN H: Ankylosing spondylitis - the female aspect. J. Rheumatol. (1998) 25:120-124.
93. ZAW W, GAGNON R, DA SILVA O: The risks of adverse neonatal outcome among preterm small for gestational age infants according to neonatal versus fetal growth standards. Pediatrics (2003) 111:1273-1277.
94. BURTON PJ, WADDELL BJ: Dual function of 11β-hydroxysteroid. dehydrogenase in placenta: Modulating placental glucocorticoid passage and local steroid action. Biol. Reprod (1999) 60:234-240.
95. BENEDIKTSSON R, LINDSAY RS, NOBLE J, SECKL JR, EDWARDS CRW: Glucocorticoid exposure in utero: New model for adult hypertension. Lancet (1993) 341:339-341.